IFNA1 and neoplasm: However, in comparison with the control group, mouse treated with the combination of IFNα-MSCs and α-PD-L1 profoundly decreased tumor growth (Fig. 7D, E) and increased survival time of tumor bearing mice over monotherapies (Fig. 7F).